KRT86

Across TCGA pan-cancer cohorts, KRT86 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of KRT86’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where KRT86 RNA is repressed in tumor relative to normal tissue. In most cancer types KRT86 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LUAD, and KIRP are the cancer types where KRT86 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT86 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−1.285	<.001	10	view →
LUAD	All	III,IV	+1.578	<.001	9	view →
KIRP	Male	All	+1.508	<.001	9	view →
KIRC	Male	All	+0.926	<.001	9	view →
LIHC	Female	All	+1.001	<.001	8	view →
COAD	Female	All	+0.680	.001	6	view →
CHOL	All	All	+1.837	<.001	5	view →
STAD	All	II,III,IV	+0.529	.003	4	view →
KICH	All	All	−0.381	.005	4	view →
LUSC	All	All	+0.520	.002	3	view →
UCEC	All	All	+0.812	.018	2	view →
PRAD	All	All	−0.475	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

KRT86–THCA

Open the THCA breakdown →